Rex Board

Pong Chen Yih, Independent Non-Executive Chairman,
Chairman, Nominating and Remuneration Committees, Member, Audit Committee

Mr Pong Chen Yih, 50, was appointed as an Independent Non-Executive Chairman on 8 May 2026. He was first appointed as an Independent Non-Executive Director on 1 August 2023 and redesignated as Lead Independent Non-Executive Director on 25 April 2024. He was last re-elected to the Board on 24 April 2026. Mr Pong is also an independent board member of Rex Technology Investments Pte. Ltd. and Xer Technologies Pte. Ltd., subsidiaries of the Group.

He has over 20 years of experience handling complex legal and financial advisory work in relation to domestic and international corporate finance and capital markets transactions. He has successfully listed over 45 companies on the Singapore Exchange. He is a Director and the Chief Operating Officer of Novus Corporate Finance Pte. Ltd., an accredited issue manager for the Singapore Exchange Mainboard listings and a Full Sponsor for Catalist. He is presently an independent director of HRnetGroup Limited, and a past board member of Grand Venture Technology Limited and Figtree Holdings Limited. Mr Pong was previously the Head of the Singapore Domestic Capital Markets Group in Baker McKenzie and prior to that, a partner in the Equity Capital Markets Group in WongPartnership LLP. He regularly speaks at local and overseas conferences and seminars on topics such as capital raising and listing requirements.

Mr Pong holds a Bachelor of Laws (Honours) from the National University of Singapore.

Mae Heng, Independent Non-Executive Director, Chairperson, Audit Committee, Member, Remuneration and Nominating Committees

Ms Mae Heng, 55, was appointed as an Independent Non-Executive Director on 4 May 2022 and was re-elected to the Board on 25 April 2025. She is also an independent board member of Rex International Investments Pte. Ltd., a subsidiary of the Group.

Ms Heng has over 16 years of experience working at Ernst & Young Singapore. She is an Independent Non-Executive Director of Chuan Hup Holdings Limited, HRnetGroup Limited, ISDN Holdings Limited and Progen Holdings Limited, and is the chairperson or a member of these companies' various board committees. She is also a Non-Independent Non-Executive Director of Ossia International Limited. Ms Heng holds directorships in her family-owned investment holding companies. She was a past board member of Novo Tellus Alpha Acquisition, Apex Healthcare Berhad and Grand Venture Technology Limited.

Ms Heng holds a Bachelor of Accountancy from the Nanyang Technological University, Singapore. She is a Fellow Chartered Accountant with the Institute of Singapore Chartered Accountants and an ASEAN Chartered Professional Accountant.

Dr Mathias Lidgren, Non-Independent Non-Executive Director; Member, Nominating Committee

Dr Mathias Lidgren, 44, was appointed as a Non-Independent Non-Executive Director on 4 May 2022 and was re-elected to the Board on 25 April 2025. He represents the interests of Limea Ltd., the controlling shareholder of the Company. Dr Mathias Lidgren is also a board member of Masirah Oil Ltd, a subsidiary of the Group.

A practising medical doctor for over a decade, Dr Lidgren has worked for the National Health Service (NHS), United Kingdom, the Hôpitaux Universitaires de Genève, Geneva, Switzerland, the Sahlgrenska University Hospital, Gothenburg, Sweden, and Skane University Hospitals in Lund, Sweden. He was also a postdoctoral researcher at the Division of Molecular Medicine and Gene Therapy, Department of Laboratory Medicine in Lund University, Sweden.

For more than 20 years, Dr Lidgren has also held multiple board positions in various private and family-owned companies involved in a range of businesses including real estate, manufacturing and medicine. He is currently an executive board member and Chief Medical Officer at Lithea AB, a pharmaceutical company based in Lund, Sweden.

Dr Lidgren holds a Doctor of Philosophy in Health Economics from the Karolinska Institutet, Sweden, a Master of Arts in Genetics, as well as a medical degree (MB BChir) from the University of Cambridge, United Kingdom, and a Bachelor of Science in Business Administration (BSBA) from the International University of Monaco. His medical degree is recognised by the Commission des professions médicales, Switzerland and Socialstyrelsen, Sweden. He is licensed to practice medicine in the canton of Geneva, Switzerland and in Sweden. He is also a board-certified specialist in clinical genetics in Sweden. Dr Lidgren is a Singapore Institute of Directors (SID) Accredited Director.